Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade
Source
CAS 214745-43-4
Species
Humanized
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Efalizumab,hu1124,ITGAL, CD11a,anti-ITGAL, CD11a
Reference
PX-TA1040
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1-kappa
Clonality
Monoclonal Antibody
Description of Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade
General information on Anti-ITGAL/CD11a(Homo sapiens) (Efalizumab) Monoclonal Antibody
Efalizumab is a recombinant monoclonal antibody to Human CD11A. Under the trade name Raptiva, it is a drug that was previously used to treat autoimmune diseases and was originally used to treat psoriasis. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and inhibits lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab has been associated with fatal brain infections.
SDS-PAGE for Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb
Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Efalizumab Biosimilar – Anti-ITGAL, CD11a mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.